BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Imwattana K, Knight DR, Kullin B, Collins DA, Putsathit P, Kiratisin P, Riley TV. Clostridium difficile ribotype 017 - characterization, evolution and epidemiology of the dominant strain in Asia. Emerg Microbes Infect 2019;8:796-807. [PMID: 31138041 DOI: 10.1080/22221751.2019.1621670] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Imwattana K, Knight DR, Kullin B, Collins DA, Putsathit P, Kiratisin P, Riley TV. Antimicrobial resistance in Clostridium difficile ribotype 017. Expert Rev Anti Infect Ther 2020;18:17-25. [PMID: 31800331 DOI: 10.1080/14787210.2020.1701436] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
2 Fuzi M, Rodriguez Baño J, Toth A. Global Evolution of Pathogenic Bacteria With Extensive Use of Fluoroquinolone Agents. Front Microbiol 2020;11:271. [PMID: 32158437 DOI: 10.3389/fmicb.2020.00271] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
3 Xu X, Luo Y, Chen H, Song X, Bian Q, Wang X, Liang Q, Zhao J, Li C, Song G, Yang J, Sun L, Jiang J, Wang H, Zhu B, Ye G, Chen L, Tang YW, Jin D. Genomic evolution and virulence association of Clostridioides difficile sequence type 37 (ribotype 017) in China. Emerg Microbes Infect 2021;10:1331-45. [PMID: 34125660 DOI: 10.1080/22221751.2021.1943538] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Guo CLT, Kwong TNY, Mak JWY, Zhang L, Lui GCY, Wong GLH, Ip M, Yu J, Sung JJY, Wu WKK, Wong SH. Trends in Incidence and Clinical Outcomes of Clostridioides difficile Infection, Hong Kong. Emerg Infect Dis 2021;27. [PMID: 34812719 DOI: 10.3201/eid2712.203769] [Reference Citation Analysis]
5 Perumalsamy S, Lim SC, Riley TV. Clostridioides (Clostridium) difficile isolated from paediatric patients in Western Australia 2019-2020. Pathology 2022:S0031-3025(22)00020-4. [PMID: 35125203 DOI: 10.1016/j.pathol.2021.10.009] [Reference Citation Analysis]
6 Lim SC, Hain-Saunders NMR, Imwattana K, Putsathit P, Collins DA, Riley TV. Genetically related Clostridium difficile from water sources and human CDI cases revealed by whole-genome sequencing. Environ Microbiol 2021. [PMID: 34693624 DOI: 10.1111/1462-2920.15821] [Reference Citation Analysis]
7 Wickramage I, Spigaglia P, Sun X. Mechanisms of antibiotic resistance of Clostridioides difficile. J Antimicrob Chemother 2021:dkab231. [PMID: 34297842 DOI: 10.1093/jac/dkab231] [Reference Citation Analysis]
8 Aguilar-zamora E, Weimer BC, Torres RC, Gómez-delgado A, Ortiz-olvera N, Aparicio-ozores G, Barbero-becerra VJ, Torres J, Camorlinga-ponce M. Molecular Epidemiology and Antimicrobial Resistance of Clostridioides difficile in Hospitalized Patients From Mexico. Front Microbiol 2022;12:787451. [DOI: 10.3389/fmicb.2021.787451] [Reference Citation Analysis]
9 Martínez-Meléndez A, Morfin-Otero R, Villarreal-Treviño L, Baines SD, Camacho-Ortíz A, Garza-González E. Molecular epidemiology of predominant and emerging Clostridioides difficile ribotypes. J Microbiol Methods 2020;175:105974. [PMID: 32531232 DOI: 10.1016/j.mimet.2020.105974] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Mutai WC, Mureithi MW, Anzala O, Revathi G, Kullin B, Burugu M, Kyany'a C, Odoyo E, Otieno P, Musila L. High Prevalence of Multidrug-Resistant Clostridioides difficile Following Extensive Use of Antimicrobials in Hospitalized Patients in Kenya. Front Cell Infect Microbiol 2020;10:604986. [PMID: 33628744 DOI: 10.3389/fcimb.2020.604986] [Reference Citation Analysis]
11 Skinner AM, Phillips ST, Merrigan MM, O'Leary KJ, Sambol SP, Siddiqui F, Peterson LR, Gerding DN, Johnson S. The Relative Role of Toxins A and B in the Virulence of Clotridioides difficile. J Clin Med 2020;10:E96. [PMID: 33396595 DOI: 10.3390/jcm10010096] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Imwattana K, Kiratisin P, Riley TV, Knight DR. Genomic basis of antimicrobial resistance in non-toxigenic Clostridium difficile in Southeast Asia. Anaerobe 2020;66:102290. [PMID: 33137436 DOI: 10.1016/j.anaerobe.2020.102290] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 [DOI: 10.1101/2020.09.21.307223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Imwattana K, Putsathit P, Collins DA, Leepattarakit T, Kiratisin P, Riley TV, Knight DR. Global evolutionary dynamics and resistome analysis of Clostridioides difficile ribotype 017. Microb Genom 2022;8. [PMID: 35316173 DOI: 10.1099/mgen.0.000792] [Reference Citation Analysis]
15 Goyal M, Hauben L, Pouseele H, Jaillard M, De Bruyne K, van Belkum A, Goering R. Retrospective Definition of Clostridioides difficile PCR Ribotypes on the Basis of Whole Genome Polymorphisms: A Proof of Principle Study. Diagnostics (Basel) 2020;10:E1078. [PMID: 33322677 DOI: 10.3390/diagnostics10121078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Collins DA, Sohn KM, Wu Y, Ouchi K, Ishii Y, Elliott B, Riley TV, Tateda K; Clostridioides difficile Asia-Pacific Study Group. Clostridioides difficile infection in the Asia-Pacific region. Emerg Microbes Infect 2020;9:42-52. [PMID: 31873046 DOI: 10.1080/22221751.2019.1702480] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
17 Gonzales-Luna AJ, Carlson TJ, Dotson KM, Poblete K, Costa G, Miranda J, Lancaster C, Walk ST, Tupy S, Begum K, Alam MJ, Garey KW. PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255. Emerg Microbes Infect 2020;9:341-7. [PMID: 32037964 DOI: 10.1080/22221751.2020.1721335] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
18 Imwattana K, Putsathit P, Knight DR, Kiratisin P, Riley TV. Molecular Characterization of, and Antimicrobial Resistance in, Clostridioides difficile from Thailand, 2017-2018. Microb Drug Resist 2021. [PMID: 33956520 DOI: 10.1089/mdr.2020.0603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
19 Wongkuna S, Janvilisri T, Phanchana M, Harnvoravongchai P, Aroonnual A, Aimjongjun S, Malaisri N, Chankhamhaengdecha S. Temporal Variations in Patterns of Clostridioides difficile Strain Diversity and Antibiotic Resistance in Thailand. Antibiotics (Basel) 2021;10:714. [PMID: 34199301 DOI: 10.3390/antibiotics10060714] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Imwattana K, Putsathit P, Leepattarakit T, Kiratisin P, Riley TV. Mild or Malign: Clinical Characteristics and Outcomes of Clostridium difficile Infection in Thailand. J Clin Microbiol 2020;58:e01217-20. [PMID: 32580954 DOI: 10.1128/JCM.01217-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ressler A, Wang J, Rao K. Defining the black box: a narrative review of factors associated with adverse outcomes from severe Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211048127. [PMID: 34646358 DOI: 10.1177/17562848211048127] [Reference Citation Analysis]
22 Bilverstone TW, Garland M, Cave RJ, Kelly ML, Tholen M, Bouley DM, Kaye P, Minton NP, Bogyo M, Kuehne SA, Melnyk RA. The glucosyltransferase activity of C. difficile Toxin B is required for disease pathogenesis. PLoS Pathog 2020;16:e1008852. [PMID: 32960931 DOI: 10.1371/journal.ppat.1008852] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Abdrabou AMM, Ul Habib Bajwa Z, Halfmann A, Mellmann A, Nimmesgern A, Margardt L, Bischoff M, von Müller L, Gärtner B, Berger FK. Molecular epidemiology and antimicrobial resistance of Clostridioides difficile in Germany, 2014-2019. Int J Med Microbiol 2021;311:151507. [PMID: 33915347 DOI: 10.1016/j.ijmm.2021.151507] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Perumalsamy S, Riley TV. Molecular Epidemiology of Clostridioides difficile Infections in Children. J Pediatric Infect Dis Soc 2021;10:S34-40. [PMID: 34791401 DOI: 10.1093/jpids/piab057] [Reference Citation Analysis]
25 Lew T, Putsathit P, Sohn KM, Wu Y, Ouchi K, Ishii Y, Tateda K, Riley TV, Collins DA. Antimicrobial Susceptibilities of Clostridium difficile Isolates from 12 Asia-Pacific Countries in 2014 and 2015. Antimicrob Agents Chemother 2020;64:e00296-20. [PMID: 32393487 DOI: 10.1128/AAC.00296-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
26 Okada Y, Okugawa S, Ikeda M, Kobayashi T, Saito R, Higurashi Y, Moriya K. Genetic diversity and epidemiology of accessory gene regulator loci in Clostridioides difficile. Access Microbiol 2020;2:acmi000134. [PMID: 32974597 DOI: 10.1099/acmi.0.000134] [Reference Citation Analysis]
27 Imwattana K, Rodríguez C, Riley TV, Knight DR. A species-wide genetic atlas of antimicrobial resistance in Clostridioides difficile. Microb Genom 2021;7. [PMID: 34793295 DOI: 10.1099/mgen.0.000696] [Reference Citation Analysis]
28 Acuña-Amador L, Quesada-Gómez C, Rodríguez C. Clostridioides difficile in Latin America: A comprehensive review of literature (1984-2021). Anaerobe 2022;:102547. [PMID: 35337973 DOI: 10.1016/j.anaerobe.2022.102547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Cheng JW, Liu C, Kudinha T, Xiao M, Fan X, Yang CX, Wei M, Liang GW, Shao DH, Xiong ZJ, Hou X, Yu SY, Wang Y, Yang QW, Su JR, Xu YC. The tcdA-negative and tcdB-positive Clostridium difficile ST81 clone exhibits a high level of resistance to fluoroquinolones: a multi-centre study in Beijing, China. Int J Antimicrob Agents 2020;56:105981. [PMID: 32330584 DOI: 10.1016/j.ijantimicag.2020.105981] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Knight DR, Imwattana K, Kullin B, Guerrero-Araya E, Paredes-Sabja D, Didelot X, Dingle KE, Eyre DW, Rodríguez C, Riley TV. Major genetic discontinuity and novel toxigenic species in Clostridioides difficile taxonomy. Elife 2021;10:e64325. [PMID: 34114561 DOI: 10.7554/eLife.64325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Doll M, Marra AR, Apisarnthanarak A, Al-Maani AS, Abbas S, Rosenthal VD. Prevention of Clostridioides difficile in hospitals: A position paper of the International Society for Infectious Diseases. Int J Infect Dis 2021;102:188-95. [PMID: 33122100 DOI: 10.1016/j.ijid.2020.10.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
32 Putsathit P, Hong S, George N, Hemphill C, Huntington PG, Korman TM, Kotsanas D, Lahra M, McDougall R, McGlinchey A, Moore CV, Nimmo GR, Prendergast L, Robson J, Waring L, Wehrhahn MC, Weldhagen GF, Wilson RM, Riley TV, Knight DR. Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015-18. J Antimicrob Chemother 2021;76:1815-21. [PMID: 33895826 DOI: 10.1093/jac/dkab099] [Reference Citation Analysis]
33 Kordus SL, Thomas AK, Lacy DB. Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics. Nat Rev Microbiol 2021. [PMID: 34837014 DOI: 10.1038/s41579-021-00660-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Chang F, Liu C, Sun F, Lin C. Optimizing laboratory workflow for the diagnosis of Clostridiodes difficile infection in a medical center in Northern Taiwan. Journal of Microbiology, Immunology and Infection 2021;54:284-9. [DOI: 10.1016/j.jmii.2019.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]